Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Total Current Liabilities (2016 - 2025)

Apyx Medical (APYX) has disclosed Total Current Liabilities for 16 consecutive years, with $11.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Current Liabilities rose 9.13% year-over-year to $11.7 million, compared with a TTM value of $11.7 million through Dec 2025, up 9.13%, and an annual FY2025 reading of $11.7 million, up 9.13% over the prior year.
  • Total Current Liabilities was $11.7 million for Q4 2025 at Apyx Medical, up from $11.0 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $19.0 million in Q2 2023 and bottomed at $9.5 million in Q1 2025.
  • Average Total Current Liabilities over 5 years is $11.8 million, with a median of $11.1 million recorded in 2022.
  • The sharpest move saw Total Current Liabilities surged 67.63% in 2023, then tumbled 44.09% in 2024.
  • Year by year, Total Current Liabilities stood at $13.2 million in 2021, then fell by 10.26% to $11.8 million in 2022, then rose by 7.51% to $12.7 million in 2023, then dropped by 15.85% to $10.7 million in 2024, then rose by 9.13% to $11.7 million in 2025.
  • Business Quant data shows Total Current Liabilities for APYX at $11.7 million in Q4 2025, $11.0 million in Q3 2025, and $10.6 million in Q2 2025.